Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Summary
This is a multicenter, open-label, dose-escalation and dose expansion, and cohort-expansion phase Ib/II clinical study to evaluate the safety and antitumor efficacy of SYH2051 in combination with Irinotecan Hydrochloride Liposome Injection in Patients with Advanced Solid Tumors.
Official title: A Phase Ib/ II Clinical Study to Evaluate the Safety and Efficacy of SYH2051 in Combination With Irinotecan Hydrochloride Liposome in Patients With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
154
Start Date
2026-11-30
Completion Date
2029-12-30
Last Updated
2026-11-03
Healthy Volunteers
No
Conditions
Interventions
SYH2051
SYH2051 is an oral medication taken once daily, with dosage selected according to the dose group.
Irinotecan Hydrochloride Liposome.
Irinotecan Hydrochloride Liposome is administered by intravenous infusion every 2 weeks (Q2W)
Locations (1)
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China